Sonablate, intended for use in the focused ablation of prostate tissue, first gained regulatory clearance in October 2015.
The new device contains an updated physical structure and software interface, offering new capabilities to monitor tissue changes and provide altered ultrasound delivery sequences, among other features.
SonaCare expects the new device to decrease overall procedure time by as much as 40 percent, according to a news release.
More articles on supply chain:
6 noteworthy drugs the FDA approved in 2016
HHS Sec. Burwell’s advice to Dr. Tom Price: Prioritize cybersecurity
Valeant to sell off $2B in assets to ease debt: 3 takeaways
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
